Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer

BackgroundProstate cancer is one of the most prevalent cancers in males in the United States and amongst the leading causes of cancer related deaths. A particularly virulent form of this disease is castration-resistant prostate cancer (CRPC), where patients no longer respond to medical or surgical castration. CRPC is a complex, multifaceted and heterogeneous malady with limited standard treatment options.ResultsThe growth and progression of prostate cancer is a complicated process that involves multiple pathways. The signaling network comprising the integral constituents of the signature pathways involved in the development and progression of prostate cancer is modeled as a combinatorial circuit. The failures in the gene regulatory network that lead to cancer are abstracted as faults in the equivalent circuit and the Boolean circuit model is then used to design therapies tailored to counteract the effect of each molecular abnormality and to propose potentially efficacious combinatorial therapy regimens. Furthermore, stochastic computational modeling is utilized to identify potentially vulnerable components in the network that may serve as viable candidates for drug development.ConclusionThe results presented herein can aid in the design of scientifically well-grounded targeted therapies that can be employed for the treatment of prostate cancer patients.

[1]  Johann S de Bono,et al.  Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer , 2009, Clinical Cancer Research.

[2]  Oliver Sawodny,et al.  ON/OFF and Beyond - A Boolean Model of Apoptosis , 2009, PLoS Comput. Biol..

[3]  Jong Soon Kang,et al.  Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration‐resistant prostate cancer , 2015, The Prostate.

[4]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[5]  P. Ghazal,et al.  Logic models of pathway biology. , 2008, Drug discovery today.

[6]  Jie Han,et al.  Asynchronous Stochastic Boolean Networks as Gene Network Models , 2014, J. Comput. Biol..

[7]  N. Agarwal,et al.  Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer , 2013, Prostate cancer.

[8]  Rui-Sheng Wang,et al.  Boolean modeling in systems biology: an overview of methodology and applications , 2012, Physical biology.

[9]  Aniruddha Datta,et al.  Hypoxia Stress Response Pathways: Modeling and Targeted Therapy , 2017, IEEE Journal of Biomedical and Health Informatics.

[10]  Aniruddha Datta,et al.  Systems biology Advance Access publication December 30, 2010 Cancer therapy design based on pathway logic , 2022 .

[11]  Nedumparambathmarath Vijesh,et al.  Modeling of gene regulatory networks: A review , 2013 .

[12]  Rahul Aggarwal,et al.  Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment , 2011, The oncologist.

[13]  Jianfeng Xu,et al.  Androgen Receptor Signaling in Prostate Cancer: New Twists for an Old Pathway , 2012 .

[14]  Z. Hall.  Cancer , 1906, The Hospital.

[15]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[16]  E. Yu,et al.  Targeted therapy in the treatment of castration-resistant prostate cancer. , 2013, Oncology.

[17]  Xueying Mao,et al.  The complexity of prostate cancer: genomic alterations and heterogeneity , 2012, Nature Reviews Urology.

[18]  James T. Murray,et al.  Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells , 2012, Bioscience reports.

[19]  R. Albert,et al.  Network model of survival signaling in large granular lymphocyte leukemia , 2008, Proceedings of the National Academy of Sciences.

[20]  T. Helikar,et al.  Emergent decision-making in biological signal transduction networks , 2008, Proceedings of the National Academy of Sciences.

[21]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[22]  Martin E. Gleave,et al.  Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. , 2015, European urology.

[23]  Kartik Mohanram,et al.  Reliability Analysis of Logic Circuits , 2009, IEEE Transactions on Computer-Aided Design of Integrated Circuits and Systems.

[24]  Aurélien Naldi,et al.  Dynamical analysis of a generic Boolean model for the control of the mammalian cell cycle , 2006, ISMB.

[25]  N. Agarwal,et al.  Novel molecular targets for the therapy of castration-resistant prostate cancer. , 2012, European urology.

[26]  Réka Albert,et al.  Boolean modeling: a logic‐based dynamic approach for understanding signaling and regulatory networks and for making useful predictions , 2014, Wiley interdisciplinary reviews. Systems biology and medicine.

[27]  Su Qu,et al.  PI3K-AKT-mTOR Pathway is Dominant over Androgen Receptor Signaling in Prostate Cancer Cells , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[28]  Jie Han,et al.  Identification of Potential Drug Targets in Cancer Signaling Pathways using Stochastic Logical Models , 2016, Scientific Reports.

[29]  Clare E. Giacomantonio,et al.  A Boolean Model of the Gene Regulatory Network Underlying Mammalian Cortical Area Development , 2010, PLoS Comput. Biol..

[30]  Melvin A. Breuer,et al.  Digital systems testing and testable design , 1990 .

[31]  Andrew J Armstrong,et al.  Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. , 2013, Endocrine-related cancer.

[32]  Hao Chen,et al.  A Stochastic Computational Approach for Accurate and Efficient Reliability Evaluation , 2014, IEEE Transactions on Computers.

[33]  T. Miller,et al.  Therapeutic targeting of cancers with loss of PTEN function. , 2014, Current drug targets.

[34]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[35]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[36]  V. Lorusso,et al.  Castration-Resistant Prostate Cancer: Targeted Therapies , 2011, Chemotherapy.

[37]  Jie Han,et al.  Stochastic Boolean networks: An efficient approach to modeling gene regulatory networks , 2012, BMC Systems Biology.

[38]  Stuart A. Kauffman,et al.  The origins of order , 1993 .

[39]  A. Abdi,et al.  Fault Diagnosis Engineering of Digital Circuits Can Identify Vulnerable Molecules in Complex Cellular Pathways , 2008, Science Signaling.

[40]  H. Scher,et al.  Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.

[41]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[42]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..